

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0004US1	Application No. 10/575,438
		Applicant Wheeler et al.	
		Filing Date April 11, 2006	Group Art Unit 1642

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,643,786	07/01/1997	Cohen et al.			
	2	5,788,963	08/04/1998	Murphy et al.			
	3	5,849,589	12/14/1998	Tedder et al.			
	4	5,851,756	12/22/1998	Steinman et al.			
	5	5,994,126	11/30/1999	Steinman et al.			
	6	6,010,905	01/04/2000	Cohen			
	7	6,037,135	03/14/2000	Kubo et al.			
	8	6,077,519	05/20/2000	Storkus et al.			
	9	6,479,286	11/12/2002	Nelson et al.			
	10	6,482,405	11/19/2002	Tahara et al.			
	11	6,514,942	02/04/2003	Ioannides et al.			
	12	6,537,560	03/25/2003	Kawakami et al.			
	13	7,247,480	07/24/2007	Waldmann et al.			
	14	7,338,929	03/04/2008	Debinski et al.			
	15	2004/0072246	04/15/2004	Martin et al.			
	16	2004/0197903	10/07/2004	Pestano			
	17	2004/0203143	10/14/2004	Tjoa et al.			
	18	2005/0059151	03/17/2005	Bosch			
	19	2006/0204509	09/14/2006	Harty et al.			
	20	2007/0098776	05/03/2007	Fikes et al.			
	21	2007/0167375	07/19/2007	Okada et al.			
	22	2008/0107668	05/08/2008	Philip et al.			
	23	2008/0199484	08/21/2008	Yu et al.			
	24	2008/0206286	08/28/2008	Yu			
	25	2008/0311141	12/18/2008	Yu et al.			
	26	2008/0311142	12/18/2008	Yu et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0004US1	Application No. 10/575,438
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Wheeler et al.	
		Filing Date April 11, 2006	Group Art Unit 1642

(37 CFR §1.98(b))

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	27	WO 95/21862	08/17/1995	WIPO				
	28	WO 96/18409	06/20/1996	WIPO				
	29	WO 00/24778	05/04/2000	WIPO				
	30	WO 00/38730	07/06/2000	WIPO				
	31	WO 01/08636	02/08/2001	WIPO				
	32	WO 01/41741	06/14/2001	WIPO				
	33	WO 02/68474	09/06/2002	WIPO				
	34	WO 03/035004	05/01/2003	WIPO				
	35	WO 2005/037995	04/28/2005	WIPO				
	36	WO 2005/079581	09/01/2005	WIPO				
	37	WO 2008/039874	04/03/2008	WIPO				
	38	WO 2008/039969	04/03/2008	WIPO				
	39	WO 2008/039974	04/03/2008	WIPO				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document	
		Author	Title
	40	ABDEL-WAHAB et al., "Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity," Cell. Immunol., 186:63-74 (1998)	
	41	AKASAKI et al., "Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model," J. Immunother., 24:106-113 (2001)	
	42	AKASAKI et al., "Dendritic cell-based immunotherapy for malignant gliomas," Expert Rev. Neurother., 5:497-508 (2005)	
	43	AKASAKI et al., "Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma," J. Immunol., 173:4352-59 (2004)	
	44	AKASAKI et al., "T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches," Front. Biosci., 10:2908-21 (2005)	
	45	CANDIDO et al., "Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents," Cancer Res., 61:228-236 (2001)	
	46	CASEY et al., "Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine," Immunology, 110:105-111 (2003)	
	47	DIETZ, "Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia," Croatian Med. J., 42:428-435 (2001)	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0004US1	Application No. 10/575,438
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Wheeler et al.	
		Filing Date April 11, 2006	Group Art Unit 1642

(37 CFR §1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	48	EHTESHAM et al., "Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats," J. Immunother., 26:107-116 (2003)
	49	EHTESHAM et al., "Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials," Cancer Control, 11:192-207 (2004)
	50	GATZA et al., "Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma," J. Immunol., 169:5227-35 (2002)
	51	GEIGER et al., "Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression," Cancer Res., 61:8513-19 (2001)
	52	GILBOA et al., "Immunotherapy of cancer with dendritic-cell-based vaccines," Cancer Immunol. Immunother., 46:82-87 (1998)
	53	HIRSCHMANN-JAX et al., "A distinct 'side population' of cells with high drug efflux capacity in human tumor cells," Proc. Natl. Acad. Sci. USA, 39:14228-33 (2004)
	54	LIU et al., "Cancer vaccines: a novel strategy to sensitize malignant glioma to chemotherapy," Expert Rev. Neurother., 7:1235-37 (2007)
	55	LIU et al., "Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma," Cancer Control, 10:138-147 (2003)
	56	LIU et al., "HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells," Cancer Res., 64:4980-86 (2004)
	57	LIU et al., "Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response," Eur. J. Immunol., 34:1680-87 (2004)
	58	LUPTRAWAN et al., "Dendritic cell immunotherapy for malignant gliomas," Rev. Recent Clin. Trials, 3:10-21 (2008)
	59	MEHTA-DAMANI et al., "Generation of antigen-specific CD4+ T cell lines from naïve precursors," Eur. J. Immunol., 5:1206-11 (1995)
	60	MEHTA-DAMANI et al., "Generation of antigen-specific CD8+ CTLs from naïve precursors," J. Immunol., 153:996-1003 (1994)
	61	MELCHER et al., "Dendritic cells for the immunotherapy of cancer," Clin. Oncol., 14:185-192 (2002)
	62	MI et al., "Induced apoptosis supports spread of adenovirus vectors in tumors," Hum. Gene Ther., 12:1343-52 (2001)
	63	PARMIANI et al., "Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?" J. Natl. Cancer Inst., 94:805-818 (2002)
	64	RISSOAN et al., "Reciprocal control of T helper cell and dendritic cell differentiation," Science, 283:1183-86 (1999)
	65	SONG et al., "Strategies to improve dendritic cell-based immunotherapy against cancer," Yonsei Med. J., 45(Suppl):48-52 (2004)
	66	STEINBRINK et al., "CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity," Blood, 99:2468-76 (2002)
	67	TAKAGI et al., "Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells," Cancer Lett., 213:49-55 (2004)
	68	WHEELER et al., "Cellular immunity in the treatment of brain tumors," Clin. Neurosurg., 51:132-139 (2004)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0004US1	Application No. 10/575,438
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Wheeler et al.	
		Filing Date April 11, 2006	Group Art Unit 1642
(37 CFR §1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	69	YAMAZAKI et al., "Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells," J. Exp. Med., 198:235-247 (2003)
	70	YOUNG et al., "Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells," J. Exp. Med., 171:1315-32 (1990)
	71	YU et al., "Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma," Cancer Res., 64:4973-79 (2004)
	72	ZITVOGEL et al., "Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-1 associated cytokines," J. Exp. Med., 183:87-97 (1996)

Examiner Signature /Laura B. Goddard/	Date Considered 08/14/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	